Onset of vaping-related deaths implicates product liability law

By Lexi W. Myer

As of Oct. 4, the Centers for Disease Control and Prevention reported 1,080 cases of lung injury and 18 deaths in patients with a history of e-cigarette product use, commonly known as vaping. The CDC also found that most of these patients report a history of using THC-containing products and that “[t]he latest national and regional findings suggest products containing THC play a role in the outbreak.” Although the CDC has not yet identified the specific cause of these lung injuries or connected them to a particular device or product, a New York State Department of Health update reported that laboratory tests results showed high levels of Vitamin E acetate in nearly all cannabis-containing vape products it analyzed.

As a result, the department is investigating the health effects of Vitamin E acetate when inhaled “because its oil-like properties could be associated with the observed symptoms.” However, researchers at the Mayo Clinic are finding that while oils are possibly playing a role in vaping-related lung injuries or connected them to a particular device or product, a New York State Department of Health update reported that laboratory tests results showed high levels of Vitamin E acetate in nearly all cannabis-containing vape products it analyzed.

In California, the sale of contaminated vaping products implicates product liability law, which recognizes causes of action for manufacturing defects, design defects and warning defects. See Rest.3d Torts, Products Liability, Section 2. “Manufacturing defects can arise … when a flaw in the manufacturing process creates a product that differs from what the manufacturer intended.” Webb v. Special Electric Co., Inc., 63 Cal. 4th 167, 180 (2016). “Design defects appear in products that, although properly manufactured, are dangerous because they lack a critical feature needed to ensure safe use.” Id. The third type of defect involves a product that is dangerous because it lacks adequate warnings or instructions.
of component parts, on the basis that while these sellers are responsible for the defects in their own products, they “cannot reasonably be expected to monitor the development of all potential products into which their components are integrated.” Id. at 183. These components can be either manufactured or raw materials. Id. A bulk supplier is liable for contaminated raw materials, but a “basic” raw material cannot be defectively designed. See Rest.3d Torts, Products Liability, Section 5, com. e, at 134. These defenses could become critical when the FDA investigation pinpoints where in the supply chain potential defects may arise.

Preemption may also play a role in these cases. In the tobacco arena, the California Court of Appeal ruled that certain state law failure to warn claims were preempted based upon the Federal Cigarette Labeling and Advertising Act of 1969. Specifically, “[f]ailure-to-warn causes of action for breach of warranty, intentional fraud and misrepresentation of a material fact by either a false representation or concealment, and conspiracy were not included within the preemptive reach of the Act.” Id.

In December 2018, the Agriculture Improvement Act of 2018, Pub. L. 115-334 (the 2018 Farm Bill) was signed into law, which states that cannabis plants and derivatives that contain more than 0.3% THC on a dry weight basis are no longer controlled substances. According to the FDA, the 2018 Farm Bill “explicitly preserved FDA’s authority to regulate products containing cannabis or cannabis-derived compounds.” Id. Therefore, the “FDA treats products containing cannabis or cannabis-derived compounds as it does any other FDA-regulated products … regardless of whether the cannabis or cannabis-derived compounds are classified as hemp under the 2018 Farm Bill.” Id.

As a general rule, “the historic police powers of the States [are] not to be superseded by … Federal Act unless that [is] the clear and manifest purpose of Congress. … However, when the state regulates in an area where there has been a history of significant federal presence the ‘assumption’ of non-pre-emption is not triggered.” Major v. R.J Reynolds Tobacco Co., 14 Cal. App. 5th 1179, 118 (2017). Until recently, cannabis has been largely regulated by the states. It will be interesting to see how the Farm Bill and the FDA’s authority will affect or restrict the application of state product liability law to cannabis vaping products.

Given the apparent link between cannabis-containing vape and the alarming increase in lung injury, tighter industry regulation and control will inevitably ensue, as will product liability litigation. In larger cases where firms may represent multiple plaintiffs alleging the same types of injuries and defects, mediation is a useful tool for settlement. Once liability has been established, defendants can settle multi-plaintiff cases globally and appoint a special master to allocate funds among the claimants. The special master and the parties can work together to establish criteria and values for various categories of injuries, allowing cases that fall into those categories to be quickly resolved. More factually intensive cases can then be reserved for individual mediations. This type of global settlement saves the parties from having to litigate each case to conclusion or from mediating each case one by one, both of which are more expensive and time-consuming options.

Lexi Myer handled complex federal MDL and state coordinated matters and class actions as a litigator and now serves as a JAMS neutral based in Los Angeles. She resolves product liability cases and has an interest in tobacco, cannabis and pharmaceutical products. Email her at lmyer@jamsadr.com.